← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Enhabit, Inc.: Revenue grew 2.4% to $1.06B from $1.035B. Net loss narrowed to $4.6M from $156M. Free cash flow grew 38.8% to $65.8M from $47.4M. Operating margin expanded 1264 bps to 1.52%. Enhabit, Inc.'s annual comparison also shows stock compensation grew faster than revenue; capital spending grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 2.4% to $1.06B from $1.035BOK
- Profitability — Net loss narrowed to $4.6M from $156MOK
- Cash flow — Free cash flow grew 38.8% to $65.8M from $47.4MOK
- Margins — Operating margin expanded 1264 bps to 1.52%OK
- Accounting — No overriding statistical warningNote
- Insiders — 1 purchase and 3 salesOK
Business
We operate our business in two segments, Home Health and Hospice.
Where the revenue comes from
Fiscal 2025, as Enhabit, Inc. reports it. History and quarterly detail are in the app.
- Home Health$813.8M
- Hospice$246.2M
Leadership changes
From Enhabit, Inc.'s own filings, the day they're filed.
- Barbara A. Jacobsmeyer · Chief Executive Officer · departureeff. 2026-07-31
- Collin McQuiddy · President · appointmenteff. 2024-08-05
- Ryan Solomon · Chief Financial Officer · departure
Latest filings
- 8-K · Company announcement2026-05-15
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-07
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Enhabit, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.